Results of AGM

Summary by AI ^BETAClose X

Sareum Holdings PLC announced that all resolutions were duly passed at its Annual General Meeting, including the receipt of financial statements with 97.7% of votes in favour, approval of the Directors' Remuneration Report with 87.7% in favour, and the re-election of Mr John Reader as Director with 91.9% in favour. The re-appointment of auditors and authorization for the audit committee to determine auditor remuneration also received strong support, with 97.4% and 92.3% of votes respectively. Resolutions concerning directors' authority to allot new shares and to disapply pre-emption rights passed with 89.4% and 89.5% of votes in favour, respectively.

Disclaimer*

Sareum Holdings PLC

09 December 2025

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

Details of the voting results are shown in the table below:

Ordinary Resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive the financial statements for the year	12,053,451	97.7	283,614	2.3	12,809,354	9.3	472,289
2. Receive and approve the Directors' Renumeration Report for the year	11,035,739	87.7	1,544,196	12.3	12,809,354	9.3	229,419
3. Re-elect Mr John Reader as Director of the Company	11,343,737	91.9	1,000,383	8.1	12,809,354	9.3	465,234
4. Re-appoint Moore Kinston Smith LLP as auditor	12,356,748	97.4	325,897	2.6	12,809,354	9.3	126,709
5. Authorise the audit committee to determine auditor renumeration	11,741,351	92.3	977,756	7.7	12,809,084	9.3	89,977
6. Directors' authority to allot new shares	11,305,713	89.4	1,333,162	10.6	12,809,354	9.3	170,479
Special Resolution
7. Authority to disapply pre-emption rights	11,179,080	89.5	1,312,944	10.5	12,809,354	9.3	317,330
8. Authority to hold general meetings	11,955,500	96.8	391,565	3.2	12,809,354	9.3	462,289

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact:

Sareum Holdings plc

Stephen Parker, Executive Chaiman

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Singer Capital Markets (Joint Corporate Broker)

Phil Davies

020 7496 3000

Oberon Capital (Joint Corporate Broker)

Mike Seabrook / Nick Lovering

020 3179 5300

ICR Healthcare (Financial PR)

Jessica Hodgson / Davide Salvi

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease

The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END